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Abstract 
Osteoporosis is very common, particularly in post-menopausal women and is characterized by a decrease in bone 
mass and strength. Osteoporosis also affects the jawbone and it is considered a potential contraindication to place-
ment of dental implants. The present paper reviews the literature regarding the effect of osteoporosis on osseointe-
gration of implants. Experimental models have shown that osteoporosis affects the process of osseointegration, 
which can be reversed by treatment. However, studies in subjects with osteoporosis have shown no differences 
in survival of the implants compared to healthy individuals. Therefore, osteoporosis cannot be considered a con-
traindication for implant placement. Oral bisphosphonates are the most commonly used pharmacological agents in 
the treatment of osteoporosis. Although there have been cases of osteonecrosis of the jaw in patients treated with 
bisphosphonates, they are very rare and it is more usually associated with intravenous bisphosphonates in patients 
with neoplasms or other serious diseases. Nevertheless, patients treated with bisphosphonates must be informed in 
writing about the possibility of this complication and must give informed consent. Ceasing to use bisphosphonates 
before implant placement does not seem to be necessary.
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Introduction
Osteoporosis is a systemic skeletal disease character-
ized by reduced bone strength that predisposes to an 
increased risk of fractures (1). It is a very common 
disease which affects an estimated 300 million people 
worldwide. It is prevalent in females and its incidence 
increases with age. In Spain it is estimated that osteo-
porosis affects 2 million women, with prevalence above 
50% in women older than 70 years. It is characterized by 
a deterioration of bone microarchitecture with reduced 
bone mass and strength and increased fragility. The re-
sistance reflects the amount of bone density and bone 
quality. Bone density is determined by the maximum 
value of bone mass (measured in grams per cm2) and 
the magnitude of their loss. The bone quality is made up 
of different factors that influence bone fragility (micro-
architecture, bone turnover, or the microfractures and 
degree of mineralization).
The diagnosis of osteoporosis was established based 
on the classical values of bone mineral density (BMD) 
achieved in the bone densitometry, so that osteoporosis 
was considered when the T-score of less than -2.5 SD 
(the T number of standard deviations that a subject de-
viates from the average BMD of a population group of 
healthy young women). Currently the BMD is only con-
sidered a risk factor that must be assessed in the context 
of age, sex, smoking, body weight, family history and 
/ or personal fracture, etc... The most frequent risk fac-
tors for osteoporosis are present in Table 1. Thus, the 
decision to treat or not the patient will be based not only 
on the result of the density but also on risk factors (1). 
On the one hand, we use the term primary osteoporosis 
for those situations in which the decrease in bone mass, 
can be explained by involutional changes of aging, as 
well as the hormonal changes of menopause. On the 
other hand, we use the concept of secondary osteoporo-
sis for the one caused or emphasized by other diseases 
or medications (2).
There are different treatments for osteoporosis, all aimed 
at reducing the risk of fractures. Thus, estrogen treat-
ment in post-menopausal women, selective modulators 
of estrogen receptors (especially raloxifene), calcitonin, 
a recombinant form of parathormone (teriparatide), 
strontium ralenate, and especially bisphosphonates, are 
drugs widely used in clinical practice (3).
The use of dental implants in patients with osteoporo-
sis, whether being treated for it or not, is a controversial 
topic to be discussed in depth in this article.
Effects of osteoporosis on osseointegration of 
implants
Osseointegration, which is measured by the percent-
age of contact between the surface of the implant and 
the bone, can be affected not only by the characteris-
tics of the implant and surgical procedure, but also by 
patient-dependent variables that can affect the quantity 
and quality of bone. To achieve the osseointegration of 
implants is necessary to secure their adequate primary 
stability. Thus, osteoporosis, characterized by bone 
loss, alteration of the microstructure and the reduction 
in the regenerative capacity of bone, has been consid-
ered a possible contraindication or a risk factor for den-
tal implant placement. 
It has been established the hypothesis that osteoporosis 
affects the jaws in the same manner as other bones of 
the skeleton, and also that altered bone metabolism may 
reduce the scarring around the implants.
1. High risk factors
- Age over 65 
- Estrogen deficiency: early physiological or 
surgical menopause (<45 years), primary or 
secondary amenorrhea of more than one year. - 
Prior osteoporotic fracture 
- Treatment with corticosteroids (5 mg / day for 
3 months or more of prednisone or equivalent) 
- Endocrine diseases: Hyperthyroidism,   Hyper-
parathyroidism,  Male hypogonadism 
- Osteoporotic fracture in first-degree relative  - 
Low birth weight (<40 kg or BMI <19 kg/m2) 
2. Moderate risk factors
- Physiological menopause
- Low calcium intake (<500-850 mg / day for 
prolonged periods)
- Smoking (> 20 cigarettes / day) 
- Alcoholism 
-Osteopenic diseases: gastrointestinal (malab-
sorption, bowel resection, inflammatory bowel 
disease, gastrectomy), chronic liver disease, 
transplantation, rheumatoid arthritis, chronic 
renal failure, chronic obstructive pulmonary 
disease, diabetes mellitus.  
-Drugs: lithium, anticomicial level (diphenylhi-
dantoine, phenobarbital, etc), 
L-thyroxine, heparin, immunosuppressants 
(cyclosporine), hormonal blockade (aromatase 
inhibitors and gonadotrophins), chemothera-
peutic drugs.
RISK FACTORS FOR FRACTURES
BMD compatible with osteopenia and osteopo-
rosis
Age over 65
Prior osteoporotic fracture
Osteoporotic fracture in first-degree relative
Low weight 
Increased risk of falls: muscle weakness, im-
paired gait, balance or mobility, visual or cogni-
tive deficits, history of falls, etc.
Table 1. Most important risk factors for osteoporosis 
and bone fractures. Modified by: Hortal R, Martín R, 
Fernández N (6).
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The revised literature shows that the osteoporosis in-
duced in experimental animal models, before, after or 
simultaneously with the placement of implants, alters 
the process of osseointegration, especially in trabecular 
bone, and produces a significant reduction in the bone-
implant contact. 
Duarte et al. evaluated the influence of estrogen defi-
ciency in bone around implants placed in ovariecto-
mized rats. They analyzed the bone-implant contact 
and also the area and the density of bone around the im-
plants, distinguishing the cortical region of the spongy 
region. The authors found significant differences be-
tween the study group and the control group, with lower 
values in the spongy region of the group with induced 
osteoporosis(4). 
Giro et al. analyzed the influence of estrogen deficiency 
and its treatment with alendronate and estrogen on bone 
density around osseointegrated implants in rats. The ra-
diographic analysis of bone density showed that estrogen 
deprivation has a negative effect only on the trabecular 
bone, and that treatment with estrogen and alendronate 
are effective in preventing bone loss around osseointe-
grated implants. In this sense, there are other studies 
that investigate the effects of replacement therapy with 
estrogen on bone healing around implants in animals 
with osteoporosis. There were positive results which 
lead to consider this treatment to improve the long-term 
success of implants in postmenopausal patients (5). 
There are histological studies in humans conducted on 
osseointegrated implants which are removed to patients 
with osteoporosis by a prosthetic failure. They show 
healthy bone in close contact with the implant surface 
and the percentages of bone-implant contact confirm 
that osseointegration was produced (6,7). 
Shibili et al. performed a comparative histological anal-
ysis between implants with load removed in patients 
with and without osteoporosis. The percentages of bone-
implant contact did not show differences between both 
groups. The histomorphometric results were not dif-
ferent either between groups once the osseointegration 
was established. These data suggest that osteoporosis 
cannot be considered a contraindication to placement of 
implants in patients with osteoporosis (8).
Implants in subjects with osteoporosis 
The success of osseointegration depends largely on the 
health status of the patient. Although the prevalence of 
osteoporosis increases with age and after menopause, 
the literature reviewed does not show the relationship 
of the implant failure rate with age and sex. The tactile 
valuation of bone quality during the preparation of the 
implant area, and the already achieved primary stabil-
ity, bring more information that densitometric measure-
ments of peripheral bones about the probability of fail-
ure (9). 
The reduction of bone density and of mineral content of 
peripheral bones has been associated with high resorp-
tion and atrophy of edentulous jaws, but no relationship 
was found with greater loss of implants (10). In a study 
to evaluate osseointegration in postmenopausal women 
aged between 48 and 70, 19 of them with a densitomet-
ric diagnosis of osteoporosis and 20 whose diagnosis 
was normal, 82 mandibular implants  were placed (39 in 
the osteoporosis group and 43 in the control group) and 
osseointegration was analysed  after 9 months. Results 
determined by panoramic x-rays showed no significant 
differences between the group of osteoporosis and the 
control group. Also histological analysis of jaw biop-
sies showed no differences in bone formation and bone 
resorption between the two groups. The failure rate of 
1.2% (only one implant lost) is compatible with the lit-
erature and cannot be attributed to osteoporosis (11). In 
another retrospective study with a follow up to 3 years 
and 4 months for 70 implants placed in patients diag-
nosed with osteoporosis at lumbar level of the spine and 
hip, there was a success rate of 97% for the maxilla and 
97.3% for jaw (12). The results of the reviewed studies 
show that it is feasible to place implants in subjects with 
osteoporosis, with success rates similar to those ob-
tained in healthy subjects, even in cases in which there 
was poor quality of bone during or placement.
Bisphosphonates and dental implants. Applica-
tion in the treatment of osteoporosis 
Bisphosphonates (BP) are a group of drugs used to treat 
various bone diseases such as osteoporosis, multiple 
myeloma, metastatic bone tumor (primarily breast and 
prostate cancer), Paget’s disease and malignant hyper-
calcemia. 
Its clinical utility is based in its ability to directly in-
hibit bone resorption. The BP are deposited in the bone, 
inhibit the resorptive activity of osteoclasts and induce 
their apoptosis, prevent its formation from hematopoi-
etic precursors and stimulate the production by osteo-
blasts of a factor inhibiting osteoclasts. Some BP as 
pamidronate and zoledronic acid also present antiangio-
genic effect that makes them important agents in can-
cer therapy (13). Compounds of BP have high affinity 
for bone tissue, especially in areas that are remodeling. 
They accumulate for long periods of time in the mineral 
matrix of bone. Depending on the duration of treatment 
and BP specific requirements, those compounds of BP 
can remain for years. In the process of bone resorption 
the BP are released and can be incorporated into the 
new formed bone.
In the treatment of osteoporosis, the oral BP (in most 
cases) or intravenous pharmacological agents are the 
choice, because as result to their mechanism of action, 
they are effective in increasing bone mineral density 
and reduce the risk of fractures (14). 
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In the last 5 years a new complication has been described 
associated with treatment with BP: osteonecrosis of the 
jaw (ONJ), which consists of the appearance of foci of 
bone necrosis with exposure of maxillary or jaw bone 
and which has a slow healing process (or not heal) in 6-8 
weeks. The causal relationship between BP and ONJ is 
still in research, but there is a clear correlation with the 
systemic administration of aminobisphosphonates (15). 
In a review published in 2006 about 368 cases of ONJ, 
4.1% was found in patients who received BP for the 
treatment of osteoporosis, and 91.6% in patients treat-
ed for multiple myeloma and breast or prostate cancer. 
60% of cases occurred after dentoalveolar intervention 
and in other cases the cause was not identified (16). Re-
viewing the literature from 2003 to 2005, ONJ is mostly 
associated with BP administered by injection, and also 
with greater activity (pamidronate and zoledronic acid), 
which were used in over 80% of cases for the treatment 
of multiple myeloma and breast cancer. It has also been 
reported for the orally administered BP, including alen-
dronate, but they are of low frequency. A recent revision 
in 2007 also reported a low risk of ONJ in patients re-
ceiving oral therapy with BP (1/10.000-1/100.000) (17). 
The main factors associated with the development of ONJ 
are enumerated in table 2. As it is stated in the literature, 
more than 90% of the cases occur in patients receiving 
intravenous BP (pamidronate and zoledronic acid) for 
treatment of multiple myeloma and metastatic breast can-
cer or prostate cancer, while cases in patients receiving 
the BP orally for the treatment of osteoporosis are rare. 
The risk increases with treatment time due to the long 
half-life of these drugs, and within the oral cavity, jaw is 
the primary location of the foci of osteonecrosis.
The fact that osteonecrosis associated with the treatment 
takes place in the oral cavity and especially in the jaw 
could be explained by the constant microtrauma caused by 
the forces of chewing, which make the bone be constantly 
remodeling and BP reach there concentrations higher than 
in other parts of the body. The necessity of repairing and 
remodeling of bone increases when conducting any den-
toalveolar intervention. Depending on the dose, route and 
time of drug administration such capabilities may be seri-
ously undermined. If we also add the antiangiogenic effect 
of some BP, and the constant presence of microorganisms 
in the mouth that cause cavities and periodontal disease, 
the risk of infection of the affected area increases consid-
erably. Then, pain appears and dehiscence of the alveolar 
mucose progresses, and with all this bone exposure too.     
In a revision of 468 implants placed in 115 patients 
treated with oral BP, there was no evidence of ONJ and 
only 2 implants failed. Thus the success rate is com-
parable to that of patients not treated with BP. Implant 
placement and osseointegration during the first 3 years 
of treatment with oral BP, without the presence of oth-
er diseases or medications, can be conducted in a safe 
manner (18). Another retrospective study of the place-
ment of implants in 61 patients treated with oral BP dur-
ing an average period of 3.3 years, shows no cases of 
ONJ during follow-up (12-24 months) and the success 
rate is 100% according to Albrektsson criteria (19). 
   
Special recommendations for implant place-
ment in patients with osteoporosis treated with 
oral bisphosphonates
Although patients treated with oral BP do not require 
any special protocol, as opposed to intravenous (20), it 
is desirable to adopt a series of preventive measures, 
which aim to restore a proper state of oral health be-
fore the start of therapy with BP.  Inform the patient of 
the convenience of periodic revision and instruction in 
oral hygiene procedures to ensure adequate dental and 
periodontal health. As for the orthodontic implications 
little is known, but according to the antiresorptive ef-
fect of bone that BP have, the movement of teeth can be 
reduced or prevented after initiating treatment. 
Before any type of surgery the start of treatment with 
BP will be delayed as far as possible until the wound is 
completely healed. 
RISK FACTORS FOR DEVELOPMENT OF ONJ
Systemic factors
- Type BP
- Dosage and administration time
- Concomitant medications: immunosuppressives, steroids, 
antiangiogenic, and so on. 
- Systemic diseases: diabetes, immunodeficiencies, etc... 
Local factors
- Dental extractions
- Oral Surgery
- Trauma of the mucose by rubbing
- Periodontal disease
- Poor dental hygiene
Table 2. Risk factors for development of ONJ. BP: bisphosphonate; ONJ: osteonecrosis of 
the jaw.
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In the case the patient with osteoporosis has already 
commenced oral treatment with BP: 
- The first 3 months are not of any risk for any dental 
intervention. 
- The non-invasive treatments (fillings, endodontics, 
carvings, root debridement...) can be conducted without 
specific measures. 
- If the patient has been in treatment less than 3 years, 
the risk when undergoing extractions or surgery appears 
to be minimal, although the patient should be warned in 
the informed consent of a remote possibility of ONJ. 
- The use of other immunosuppressive medications 
such as steroids, antiangiogenic agents, or the presence 
of concomitant systemic diseases such as diabetes mel-
litus, increase the risk of ONJ before surgical action, 
although the patient has followed treatment for less than 
3 years. 
- The patient treated for more than 3 years has a higher 
risk of ONJ in case of surgical intervention. However, 
most cases of ONJ associated to oral BP according to 
the literature are found in patients treated over 10 years 
(14, 18). 
Before any invasive procedure such as implant place-
ment, most consulted authors recommend to make the 
intervention under antibiotic prophylaxis with penicil-
lin, or metronidazole in combination with a quinolone 
(in the case of allergy to penicillin). Clindamycin alone 
is not recommended because it is ineffective against 
Eikenella corrodens, Actynomices and other similar 
species that frequently colonize the oral cavity. It is also 
recommended to perform chlorhexidine rinses at 0.12% 
twice a day for 15 days. 
The possibility of stopping treatment with oral BP 2-3 
months before the intervention and until the comple-
tion of osseointegration depends on the opinion of the 
professional who prescribes it, considering the benefit 
/ risk for discontinuation of the drug. From our point 
of view, the withdrawal of the drug is not very useful, 
because the effect of BP on the bone is maintained for 
years. For this reason it is convenient to reach an agree-
ment among dentists and specialists in maxillo-facial 
surgery, and the physicians who treat osteoporosis in 
patients (rheumatologists, endocrinologists, internists, 
family doctors, etc.) (20).
It has also been recommended the establishment of the 
level of carboxyterminal telopeptide of collagen type I 
(CTX) in blood, as this telopeptide is separated of the 
collagen molecule by osteoclasts during bone resorp-
tion, and its level in blood would be proportional to the 
degree of reapsortive osteoclastic activity, which could 
have a specific value for predicting ONJ in patients un-
dergoing surgery or extractions (15): 
- If the levels of CTX are equal to or greater than 150 
pg / ml the risk of ONM in connection with surgical 
procedures is minimal. 
- If the levels of CTX are less than 150 pg / ml, it is ad-
visable to postpone the surgery, to assess the temporary 
withdrawal of the drug, and to repeat the determination 
of CTX in 4-6 months’ time. If it continues being lower 
after this time, carry on without the drug, and repeat 3 
months later. 
However, there is insufficient scientific basis about the 
predictive ability of CTX, and therefore its use should 
be considered with caution and this information should 
be detailed in the informed consent. 
Conclusions
Patients with osteoporosis have no contraindications to 
dental implant placement. The steps to take before start-
ing a surgical implant will be no different from people 
without osteoporosis. Nevertheless, proper oral hygiene 
prior to intervention will be highly advised. Although 
the risk of ONJ in subjects treated with BP is very low, 
patients should be informed and must sign consent with 
the inclusion of this specific point.
References
1. NIH Consensus Development Panel on Osteoporosis Prevention, 
Diagnosis, and Therapy. Osteoporosis: prevention, diagnosis and 
treatment. JAMA. 2001;285:785-95. 
2. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin 
North Am. 2003;32:115-34. 
3. Laroche M. Treatment of osteoporosis: all the questions we still 
cannot answer. Am J Med. 2008;121:744-7. 
4. Duarte PM, César Neto JB, Gonçalves PF, Sallum EA, Nociti FH. 
Estrogen deficiency affects bone healing around titanium implants: a 
histometric study in rats. Implant Dent. 2003;12:340-6. 
5. Giro G, Gonçalves D, Sakakura CE, Pereira RM, Marcantonio 
Júnior E, Orrico SR. Influence of estrogen deficiency and its treat-
ment with alendronate and estrogen on bone density around os-
seointegrated implants: radiographic study in female rats. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod. 2008;105:162-7. 
6. De Melo L, Piattelli A, Lezzi G, D’Avila S, Zenóbio EG, Shibli 
JA. Human histologic evaluation of a six-year-old threaded implant 
retrieved from a subject with osteoporosis. J Contemp Dent Pract. 
2008;9:99-105. 
7. Shibli JA, Grande PA, D’Avila S, Iezzi G, Piattelli A. Evaluation 
of human bone around a dental implant retrieved from a subject with 
osteoporosis. Gen Dent. 2008;56:64-7. 
8. Shibli JA, Aguiar KC, Melo L, D’Avila S, Zenóbio EG, Faveri 
M, et al. Histological comparison between implants retrieved from 
patients with and without osteoporosis. Int J Oral Maxillofac Surg. 
2008;37:321-7. 
9. Becker W, Hujoel PP, Becker BE, Willingham H. Osteoporosis 
and implant failure: an exploratory case-control study. J Periodontol. 
2000;71:625-31. 
10. Slagter KW, Raghoebar GM, Vissink A. Osteoporosis and eden-
tulous jaws. Int J Prosthodont. 2008;21:19-26. 
11. Amorim MA, Takayama L, Jorgetti V, Pereira RM. Comparative 
study of axial and femoral bone mineral density and parameters of 
mandibular bone quality in patients receiving dental implants. Os-
teoporos Int. 2007;18:703-9. 
12. Friberg B, Ekestubbe A, Mellström D, Sennerby L. Brånemark 
implants and osteoporosis: a clinical exploratory study. Clin Implant 
Dent Relat Res. 2001;3:50-6. 
13. Serra MP, Llorca CS, Donat FJ. Oral implants in patients receiv-
ing bisphosphonates: a review and update. Med Oral Patol Oral Cir 
Bucal. 2008;13:E755-60. 
14. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. 
e57
Med Oral Patol Oral Cir Bucal. 2010 Jan 1;15 (1):e52-7.                                                                                                                                                                              Osteoporosis and implants
A review of the literature on osteonecrosis of the jaw in patients with 
osteoporosis treated with oral bisphosphonates: prevalence, risk fac-
tors, and clinical characteristics. Clin Ther. 2007;29:1548-58. 
15. Gómez Font R, Martínez García ML, Olmos Martínez JM. Os-
teochemonecrosis of the jaws due to bisphosphonate treatments. Up-
date. Med Oral Patol Oral Cir Bucal. 2008;13:E318-24. 
16. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: 
bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 
2006 May 16;144(10):753-61. Review. Erratum in: Ann Intern Med. 
2006;145:235. 
17. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsen-
berg D, et al.  Bisphosphonate-associated osteonecrosis of the jaw: 
report of a task force of the American Society for Bone and Mineral 
Research. J Bone Miner Res. 2007;22:1479-91. 
18. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of plac-
ing dental implants in patients taking oral bisphosphonates: a review 
of 115 cases. J Oral Maxillofac Surg. 2008;66:223-30. 
19. Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A. Implant place-
ment with or without simultaneous tooth extraction in patients taking 
oral bisphosphonates: postoperative healing, early follow-up, and the 
incidence of complications in two private practices. J Periodontol. 
2007;78:1664-9. 
20. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez 
Veiga F, et al.  Recommendations for the prevention, diagnosis, and 
treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated 
with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:E336-
40. 
